Cephalon CEPH

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. New Analyst Report for MSB

      Stock Reports

      Tue, 26 Aug 2014

      underscore a series of transformational deals for the company, including strategic alliances and partnerships with Cephalon (now Teva) and Lonza. The management team is well credentialed with a mix of commercial and medical expertise, and

    2. New Analyst Report for Sirtex Medical Limited

      Stock Reports

      Wed, 20 Aug 2014

      single-product focus does, however, make it an attractive target. An offer of AUD 4.85 a share in 2003 by U.S. company Cephalon for Sirtex was not successful, failing to achieve the compulsory acquisition acceptance level of 90%. A long-running

    3. Why Retirement Funds Fall Short


      Tue, 2 Apr 2013

      Cephalon CEPH announced Monday that Gabitril did not ..... United States for partial seizures, but Cephalon had been working toward expanding the ..... back of regulatory delays for Sparlon, Cephalon 's drug for attention-deficit hyperactivity

    4. Teva Reports Disappointing News for Nuvigil Study in Bipolar Disorder


      Wed, 23 Jan 2013

      offset upcoming branded and generic competition for Copaxone. These events also raise our concern over the wisdom of the Cephalon acquisition. For now, however, we remain optimistic that Teva will succeed with the higher value products in its pipeline

    5. Teva Highlights Plan to Overcome Copaxone and Generic Industry Headwinds


      Wed, 12 Dec 2012

      conditions and pain) and respiratory products. This isn't particularly surprising, since these are the areas where Cephalon 's and Teva's capabilities in research and marketing had the most overlap, in our view. In light of Copaxone's

    6. Finding Good Pharma Stocks


      Thu, 10 May 2012

      To offset the expiration, Teva bought two companies in 2011: Taiyo, the third largest generics company in Japan, and Cephalon , a global biotech company. These acquisitions will add to Teva’s earnings this year. In addition, Teva entered

    7. Teva's Revenue Growth Falls Short on European Pricing Pressure


      Wed, 9 May 2012

      markets posted 30% growth. Boosted by the Cephalon acquisition, growth of 54% in Teva's ..... into our forecast. The integration of Cephalon appears on track, and Teva's operating ..... realize synergies from the integration of Cephalon .

    8. Warner Chilcott Seeks Strategic Alternatives, but We See Limited Pool of Buyers


      Mon, 30 Apr 2012

      think it could make the deal work if it were really interested. However, the firm already has its hands full integrating Cephalon and may not be interested in another large acquisition right now. Given the complexities of its portfolio, we think

    9. Acquisitions and Branded Products Propel Teva's Growth


      Wed, 15 Feb 2012

      and ongoing integration efforts for Cephalon should enable the company to meet ..... brand segment surged 68% from the Cephalon acquisition, but Teva's specialty ..... expectations. The integration of Cephalon appears on track, and we expect

    10. Teva Announces CEO Transition


      Tue, 3 Jan 2012

      generic drug utilization have been attained. The company's next growth phase, assisted by the recent acquisitions of Cephalon and emerging generic drug market operators, will require greater research and marketing capabilities going forward

    « Prev12345Next »
    Content Partners